dalteparin has been researched along with Disease Models, Animal in 119 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, the acute treatment effect of edoxaban on venous thrombosis is investigated in rats by single and multiple administrations, and compared to the conventional parenteral anticoagulants, enoxaparin and fondaparinux." | 7.80 | Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats. ( Honda, Y; Kamisato, C; Morishima, Y, 2014) |
| "In patients undergoing percutaneous coronary intervention, catheter thrombosis is more frequent with fondaparinux than heparin." | 7.77 | Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. ( Fredenburgh, JC; Liao, P; Roberts, R; Stafford, AR; Weitz, JI; Yau, JW, 2011) |
| "The antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold (LK-732, LK-639 and LK-731) and their amidoxime prodrugs (LK-658, LK-633 and LK-730) was studied in comparison to argatroban and nadroparin in two rat models of venous thrombosis, induced either by complete stasis combined with hypercoagulability (model 1) or by partial stasis combined with vessel injury (model 2)." | 7.73 | Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. ( Bozic, M; Budihna, MV; Cerne, M; Drevensek, G; Peternel, L; Stalc, A; Stegnar, M; Urleb, U; Zega, A, 2005) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 5.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| "In rat tissue factor-induced disseminated intravascular coagulation (DIC) models, an intravenous administration of danaparoid inhibited the decrease in plasma fibrinogen and platelet counts and the increase in serum fibrinogen degradation products." | 5.31 | The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat. ( Fujishima, Y; Miyake, Y; Sukamoto, T; Yokota, K, 2001) |
| "Histopathological examination of the enoxaparin and rivaroxaban groups revealed that the skin was mostly normal or intact with minimal inflammation." | 3.80 | Effects of enoxaparin and rivaroxaban on tissue survival in skin degloving injury: an experimental study. ( Alabalik, U; Alemdar, C; Azboy, I; Bulut, M; Demirtaş, A; Uçar, Y, 2014) |
| " In this study, the acute treatment effect of edoxaban on venous thrombosis is investigated in rats by single and multiple administrations, and compared to the conventional parenteral anticoagulants, enoxaparin and fondaparinux." | 3.80 | Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats. ( Honda, Y; Kamisato, C; Morishima, Y, 2014) |
| "In patients undergoing percutaneous coronary intervention, catheter thrombosis is more frequent with fondaparinux than heparin." | 3.77 | Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. ( Fredenburgh, JC; Liao, P; Roberts, R; Stafford, AR; Weitz, JI; Yau, JW, 2011) |
| "The antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold (LK-732, LK-639 and LK-731) and their amidoxime prodrugs (LK-658, LK-633 and LK-730) was studied in comparison to argatroban and nadroparin in two rat models of venous thrombosis, induced either by complete stasis combined with hypercoagulability (model 1) or by partial stasis combined with vessel injury (model 2)." | 3.73 | Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. ( Bozic, M; Budihna, MV; Cerne, M; Drevensek, G; Peternel, L; Stalc, A; Stegnar, M; Urleb, U; Zega, A, 2005) |
| "Enoxaparin and heparin significantly ameliorated the severity of dinitrobenzene sulphonic acid- and iodoacetamide-induced colitis as demonstrated by a decrease in mucosal lesion area, colonic weight and mucosal myeloperoxidase and nitric oxide synthase activities." | 3.71 | Heparin and low-molecular-weight heparin (enoxaparin) significantly ameliorate experimental colitis in rats. ( Brazowski, E; Dotan, I; Halpern, Z; Hershkoviz, R; Karmeli, F; Peled, Y; Rachmilewitz, D, 2001) |
| "The effect of dalteparin, a low molecular weight heparin, on severely antithrombin III (ATIII)-decreased disseminated intravascular coagulation (DIC) model was compared with that of unfractionated heparin (heparin)." | 3.69 | Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. ( Fukuyama, J; Hamano, S; Ichikawa, K; Misawa, K; Miyata, H; Sakuragawa, N; Tazawa, S, 1995) |
| "Mild traumatic brain injury was induced using a weight drop apparatus, with a clinical endpoint of time to right (TTR), along with histological and spectrophotometer analysis for qualitative hemorrhage." | 1.48 | The impact of enoxaparin administration in relationship to hemorrhage in mild traumatic brain injury. ( Becker, G; Dhir, T; Kaplan, M; Kriza, C; Leung, P; McGreen, B; Minimo, C; Patel, N; Randhawa, S; Samuel, S; Weiss, E; Wolanin, K, 2018) |
| "Thioacetamide (TAA) was used to induce liver fibrosis in the model group." | 1.46 | Effects of aspirin and enoxaparin in a rat model of liver fibrosis. ( Li, CJ; Liu, DL; Shi, XL; Yang, ZH, 2017) |
| "Atherosclerosis is characterized by a proliferation of vascular smooth muscle cells (VSMCs) and their migration to the intima, which induces thickening of the intima itself, but the mechanism remains poorly understood." | 1.43 | Role of parnaparin in atherosclerosis. ( Artico, M; Bonomini, F; Parnigotto, P; Rezzani, R; Rodella, LF; Taurone, S; Zamai, L, 2016) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 1.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| "Acute colitis was induced in male C57BL/6 mice by administration of dextran sulfate sodium (DSS)." | 1.42 | Orally Administered Enoxaparin Ameliorates Acute Colitis by Reducing Macrophage-Associated Inflammatory Responses. ( Eri, RD; Gueven, N; Lean, QY; Patel, RP; Peterson, GM; Randall-Demllo, S; Sohal, SS; Stewart, N, 2015) |
| "There were virtually no formation of venous thrombosis in any of the rats that received enoxaparin encapsulated in nanoparticles (0." | 1.42 | Polymeric Nanoparticles of Enoxaparin as a Delivery System: In Vivo Evaluation in Normal Rats and in a Venous Thrombosis Rat Model. ( Alessio, AM; Annichino-Bizzacchi, JM; Durán, N; Höehr, NF; Marcato, PD; Montalvão, S; Paixão, D; Pazzini, C; Prado, LB, 2015) |
| "Heparin and its derivatives are known to attenuate cancer metastasis in preclinical models, but have not been used clinically due to adverse bleeding effects." | 1.42 | Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. ( Alyahya, R; Mousa, SA; Racz, M; Stain, SC; Sudha, T, 2015) |
| "Experimental metastasis of MV3 cells in mice confirmed the relevance of VLA-4 for metastatic dissemination." | 1.38 | The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives. ( Bendas, G; Casu, B; Naggi, A; Schlesinger, M; Schmitz, P; Torri, G; Zeisig, R, 2012) |
| "We developed a murine model of venous thrombosis using, for detection, the Vevo 770(®), a micro-imaging HFUS." | 1.38 | In vivo monitoring of venous thrombosis in mice. ( Aghourian, MN; Blostein, MD; Lemarié, CA, 2012) |
| " Since repetitive dosing is usually needed for thromboprophylaxis, study objectives were to determine whether repetitive oral heparin prevented arterial thrombosis and to compare effectiveness to subcutaneous administration." | 1.38 | Repeated doses of oral and subcutaneous heparins have similar antithrombotic effects in a rat carotid arterial model of thrombosis. ( Hiebert, LM; Ping, T; Wice, SM, 2012) |
| "Hyperoxia has been shown to increase ventilator-induced lung injury, but the mechanisms regulating interaction between high tidal volume and hyperoxia are unclear." | 1.37 | Low-molecular-weight heparin reduces hyperoxia-augmented ventilator-induced lung injury via serine/threonine kinase-protein kinase B. ( Huang, CC; Kao, KC; Li, LF; Lin, HC; Liu, YY; Yang, CT, 2011) |
| " Rivaroxaban was also effective following oral dosing at 3 mg/kg." | 1.37 | Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. ( Andrade-Gordon, P; Chen, C; Connelly, MA; Damiano, BP; Huang, Z; Parry, TJ; Perzborn, E, 2011) |
| "Darexaban (YM150) is an oral factor Xa inhibitor developed for the prophylaxis of venous and arterial thromboembolic disease." | 1.37 | Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. ( Funatsu, T; Iwatsuki, Y; Kaku, S; Kawasaki, T; Moritani, Y; Sato, T; Shigenaga, T; Suzuki, M, 2011) |
| "Dalteparin was used as a reference compound." | 1.36 | Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. ( Elg, M; Johansson, K; Kjaer, M; Pehrsson, S, 2010) |
| "Oral rivaroxaban (BAY 597939) is a new, highly selective and potent direct factor-Xa (FXa) inhibitor with a predictable pharmacodynamic and pharmacokinetic profile and could therefore be an attractive antithrombotic drug." | 1.34 | Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. ( Biemond, BJ; Buetehorn, U; Büller, HR; Friederich, PW; Levi, M; Perzborn, E, 2007) |
| " We propose a new orally active heparin, Db-LHD, in a solid dosage form to effectively prevent DVT and PE." | 1.34 | A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study. ( Byun, Y; Kim, CY; Kim, SK; Lee, DY; Moon, HT; Nam, JH, 2007) |
| "After 48 h, the rate of venous thrombosis, as evaluated microscopically, was significantly decreased in hemodiluted animals (1/8) as compared with controls (10/10); in rats treated with dextran-40 (7/10) and enoxaparin (5/10) the rate of venous thrombosis was significantly higher as compared with rats of the group hemodiluted." | 1.33 | Comparative study of isovolemic hemodilution with 3% albumin, dextran-40, and prophylactic enoxaparin (LMWH) on thrombus formation at venous microanastomosis in rats. ( Campos, AD; Farina, JA; Piccinato, CE; Rossi, MA, 2006) |
| " Chronic administration of the drugs resulted in stable anticoagulation in all animals throughout the experiment." | 1.33 | Early in vivo anticoagulation inhibits the angiogenic response following hindlimb ischemia in a rodent model. ( Annichino-Bizzacchi, JM; Arruda, VR; De Paula, EV; Guillaumon, AT; Machado, TF; Nascimento, MC; Ozelo, MC; Ramos, CD, 2006) |
| "Focal cerebral ischemia was induced by the intraluminal suture, middle cerebral artery occlusion (MCAO) method." | 1.32 | The low molecular weight heparin enoxaparin reduces infarct size in a rat model of temporary focal ischemia. ( Jonas, S; Li, YS; Quartermain, D, 2003) |
| "Immediately following, the thrombus was removed, dried and weighed 24 h later." | 1.32 | Orally administered heparins prevent arterial thrombosis in a rat model. ( Hiebert, LM; Pinel, C; Wice, SM, 2004) |
| "Aspirin pretreatment increased the tongue-bleeding time, whereas the addition of CRL42796 or enoxaparin did not prolong bleeding time to a further degree." | 1.32 | Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, preven ( Driscoll, EM; Giboulot, TA; Hong, TT; Lucchesi, BR; Sherigill, A; White, AJ, 2003) |
| "In the venous thrombosis model at the maximally effective dose, C921-78 had minimal extension of ex vivo clotting parameters, while enoxaparin and unfractionated heparin demonstrated a two to sevenfold increase in activated partial thromboplastin times, and PPACK had a threefold extension of thrombin clotting times." | 1.31 | Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. ( Hollenbach, SJ; Ku, P; Lin, PH; Malinowski, J; Marlowe, CK; Scarborough, RM; Sinha, U; Wong, PW; Zhu, BY, 2000) |
| " Anti-Xa levels were elevated at 15 minutes after dosing in the OHEP/SNAC group and remained significantly elevated at 4 hours (P<0." | 1.31 | Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. ( Baughman, RA; Gonze, MD; Leone-Bay, A; Money, SR; Salartash, K; Sternbergh, WC, 2000) |
| "Thus clinical application of enoxaparin treatment in stroke warrants serious consideration." | 1.31 | Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity. ( Mary, V; Stutzmann, JM; Uzan, A; Wahl, F, 2001) |
| "In rat tissue factor-induced disseminated intravascular coagulation (DIC) models, an intravenous administration of danaparoid inhibited the decrease in plasma fibrinogen and platelet counts and the increase in serum fibrinogen degradation products." | 1.31 | The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat. ( Fujishima, Y; Miyake, Y; Sukamoto, T; Yokota, K, 2001) |
| " These data suggest that enoxaparin is more effective and potentially safer than heparin when combined with a GPIIb/IIIa receptor antagonist during rt-PA-induced coronary thrombolysis." | 1.31 | Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs. ( Bentley, RG; Bostwick, JS; Chu, V; Kasiewski, CJ; Klein, SI; Leadley, RJ; Morgan, SR; Perrone, MH; Rebello, SS, 2001) |
| "The time to formation of an occlusive thrombus in the femoral arteries averaged 69+/-5 min in the control group compared to 127+/-19, 192+/-33 and 219+/-15 min in the low-, mid- and high-dose CI-1031 groups." | 1.31 | The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. ( Hicks, GW; Janiczek-Dolphin, N; Juneau, PL; Leadley, R; McClanahan, TB; Mertz, TE; Morrison, AL; Morser, J; Peng, YW; Sullivan, ME, 2001) |
| " This study evaluates the dose-response relationship using a selectin receptor antagonist." | 1.31 | P-selectin antagonism causes dose-dependent venous thrombosis inhibition. ( Chapman, AM; Fex, BA; Greenfield, LJ; Londy, FJ; Myers, DD; Schaub, R; Wakefield, TW; Wrobleski, SK, 2001) |
| "Hemodialysis was performed on dogs, following intravenous bolus injections of LHG at dosage levels of 50, 100 and 200 IU/kg and heparin at the levels of 100 and 200 IU/kg." | 1.29 | [Anticoagulant effect of a single bolus injection of parnaparin sodium (LHG) on a hemodialysis model in dogs]. ( Akizawa, T; Kanamori, N; Katai, T; Kinugasa, E; Kodama, T; Koshikawa, S; Ohtawa, M; Okitsu, M; Sugiyama, T, 1994) |
| " Thirty-three pigs received bolus injections of 300 IU/kg with or without additional dosage during CPB and with or without subsequent protamine sulphate." | 1.29 | Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model. ( Bagge, L; Holmer, E; Malm, T; Nyström, SO; Tydén, H; Wahlberg, T, 1994) |
| "Myocardial infarction was induced by ligating the left main coronary artery." | 1.29 | The effect of low molecular weight heparin (fragmin) on myocardial neutrophil accumulation and infarct size in a rat model of myocardial infarction. ( Battler, A; Blumberg, N; Hasdai, D; Kornowski, R; Ohad, D; Varda-Bloom, N, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (12.61) | 18.2507 |
| 2000's | 43 (36.13) | 29.6817 |
| 2010's | 55 (46.22) | 24.3611 |
| 2020's | 6 (5.04) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, Y | 1 |
| Qian, J | 1 |
| Zhang, F | 1 |
| Jia, B | 1 |
| Liu, X | 1 |
| Hu, Y | 1 |
| Zhang, Q | 1 |
| Yang, Y | 1 |
| Sun, D | 1 |
| Jiang, L | 1 |
| Peternel, L | 2 |
| Stegnar, M | 2 |
| Drevensek, G | 2 |
| Budihna, MV | 2 |
| Bozic, M | 1 |
| Zega, A | 1 |
| Stalc, A | 2 |
| Cerne, M | 2 |
| Urleb, U | 1 |
| Myasnikova, VV | 1 |
| Galenko-Yaroshevskii, PA | 1 |
| Lysenkov, SP | 1 |
| Kupreishvili, VZ | 1 |
| Rizhvadze, MR | 1 |
| Sukoyan, GV | 1 |
| Biemond, BJ | 1 |
| Perzborn, E | 3 |
| Friederich, PW | 1 |
| Levi, M | 1 |
| Buetehorn, U | 1 |
| Büller, HR | 1 |
| Krupiński, K | 1 |
| Bielawiec, M | 2 |
| Breddin, HK | 2 |
| Szücs, G | 1 |
| Mikó, I | 1 |
| Ajzner, E | 1 |
| Póti, L | 1 |
| Szepesi, K | 1 |
| Furka, I | 1 |
| Iftodiĭ, AH | 1 |
| Giedrojć, J | 1 |
| Klimiuk, M | 1 |
| Radziwon, P | 1 |
| Kłoczko, J | 1 |
| Bonomini, F | 1 |
| Taurone, S | 1 |
| Parnigotto, P | 1 |
| Zamai, L | 1 |
| Rodella, LF | 1 |
| Artico, M | 2 |
| Rezzani, R | 1 |
| Riganò, R | 1 |
| Buttari, B | 1 |
| Profumo, E | 1 |
| Ionta, B | 1 |
| Bosco, S | 1 |
| Rasile, M | 1 |
| Bianchi, E | 1 |
| Bruno, M | 1 |
| Fumagalli, L | 1 |
| Celasco, G | 1 |
| Moro, L | 1 |
| Bozzella, R | 1 |
| Mangano, K | 1 |
| Quattrocchi, C | 1 |
| Aiello, C | 1 |
| Donia, M | 1 |
| Fagone, P | 1 |
| Di Marco, R | 1 |
| Sugiyama, T | 1 |
| Katai, T | 1 |
| Okitsu, M | 1 |
| Ohtawa, M | 1 |
| Kodama, T | 1 |
| Kanamori, N | 1 |
| Kinugasa, E | 1 |
| Akizawa, T | 1 |
| Koshikawa, S | 1 |
| Berkowitz, S | 1 |
| Gofrit, SG | 1 |
| Aharoni, SA | 1 |
| Golderman, V | 1 |
| Qassim, L | 1 |
| Goldberg, Z | 1 |
| Dori, A | 1 |
| Maggio, N | 1 |
| Chapman, J | 2 |
| Shavit-Stein, E | 1 |
| Fındık, O | 1 |
| Yılmaz, MY | 1 |
| Yazır, Y | 1 |
| Rençber, SF | 1 |
| Sarıhan, KK | 1 |
| Kunt, AT | 1 |
| Li, LF | 2 |
| Liu, YY | 2 |
| Lin, SW | 1 |
| Chang, CH | 1 |
| Chen, NH | 1 |
| Hung, CY | 1 |
| Lee, CS | 1 |
| Kerr, NA | 1 |
| de Rivero Vaccari, JP | 1 |
| Weaver, C | 1 |
| Dietrich, WD | 1 |
| Ahmed, T | 1 |
| Keane, RW | 1 |
| ElSaadani, M | 1 |
| Ahmed, SM | 2 |
| Jacovides, C | 2 |
| Lopez, A | 1 |
| Johnson, VE | 3 |
| Kaplan, LJ | 2 |
| Schwab, CW | 1 |
| Smith, DH | 3 |
| Pascual, JL | 3 |
| Osborne, SA | 1 |
| Masci, PP | 1 |
| Du, QS | 1 |
| Daniel, RA | 1 |
| Desilva, K | 1 |
| Vitetta, L | 1 |
| Zhao, KN | 1 |
| Seymour, RB | 1 |
| Sandri, ASS | 1 |
| Rodriguez, R | 2 |
| Costa, MM | 1 |
| Porto, SM | 2 |
| Schwingel, D | 1 |
| Vieira, MIB | 1 |
| Li, CJ | 1 |
| Yang, ZH | 1 |
| Shi, XL | 1 |
| Liu, DL | 1 |
| Cao, F | 1 |
| Liu, G | 1 |
| Wang, W | 1 |
| Wang, B | 1 |
| Wei, X | 1 |
| Lu, F | 1 |
| Yang, F | 1 |
| Kang, K | 1 |
| Wang, Y | 1 |
| Yang, J | 1 |
| Qin, K | 1 |
| Zhao, D | 2 |
| Vicci, H | 1 |
| Eblen-Zajjur, A | 1 |
| López, M | 1 |
| Crespo, G | 1 |
| Navarro, M | 1 |
| Kowaliuk, M | 1 |
| Bozsaky, E | 1 |
| Gruber, S | 1 |
| Kuess, P | 1 |
| Dörr, W | 1 |
| Suto, Y | 1 |
| Nagata, K | 2 |
| Browne, KD | 2 |
| Cognetti, J | 1 |
| Weber, MT | 1 |
| Leone, R | 1 |
| Dhir, T | 1 |
| Weiss, E | 1 |
| Wolanin, K | 1 |
| Randhawa, S | 1 |
| Samuel, S | 1 |
| Minimo, C | 1 |
| Becker, G | 1 |
| McGreen, B | 1 |
| Kriza, C | 1 |
| Patel, N | 1 |
| Kaplan, M | 1 |
| Leung, P | 1 |
| Morris, MC | 1 |
| Kassam, F | 1 |
| Bercz, A | 1 |
| Beckmann, N | 1 |
| Schumacher, F | 1 |
| Gulbins, E | 1 |
| Makley, AT | 1 |
| Goodman, MD | 1 |
| Kemik, O | 1 |
| Adas, G | 1 |
| Arikan, S | 1 |
| Gurluler, E | 1 |
| Dogan, Y | 1 |
| Toklu, AS | 1 |
| Kapran, Y | 1 |
| Kuntsal, L | 1 |
| Purisa, S | 1 |
| Kemik, A | 1 |
| Stolz, E | 2 |
| Fett, A | 1 |
| Wessels, C | 1 |
| Azboy, I | 1 |
| Demirtaş, A | 1 |
| Bulut, M | 1 |
| Alabalik, U | 1 |
| Uçar, Y | 1 |
| Alemdar, C | 1 |
| Wang, L | 1 |
| Li, L | 1 |
| Sun, Y | 1 |
| Ding, J | 1 |
| Li, J | 1 |
| Duan, X | 1 |
| Li, Y | 1 |
| Junyaprasert, VB | 1 |
| Mao, S | 1 |
| Kaya, C | 1 |
| Turgut, H | 1 |
| Cengiz, H | 1 |
| Turan, A | 1 |
| Ekin, M | 1 |
| Yaşar, L | 1 |
| Morishima, Y | 1 |
| Kamisato, C | 1 |
| Honda, Y | 1 |
| Oliveira, SN | 2 |
| Santos, GR | 1 |
| Glauser, BF | 2 |
| Capillé, NV | 1 |
| Queiroz, IN | 1 |
| Pereira, MS | 2 |
| Pomin, VH | 1 |
| Mourão, PA | 2 |
| Diaz, JA | 2 |
| Wrobleski, SK | 5 |
| Alvarado, CM | 2 |
| Hawley, AE | 4 |
| Doornbos, NK | 1 |
| Lester, PA | 1 |
| Lowe, SE | 1 |
| Gabriel, JE | 1 |
| Roelofs, KJ | 1 |
| Henke, PK | 3 |
| Schaub, RG | 4 |
| Wakefield, TW | 6 |
| Myers, DD | 6 |
| Lean, QY | 1 |
| Eri, RD | 1 |
| Randall-Demllo, S | 1 |
| Sohal, SS | 1 |
| Stewart, N | 1 |
| Peterson, GM | 1 |
| Gueven, N | 1 |
| Patel, RP | 1 |
| Pazzini, C | 1 |
| Marcato, PD | 1 |
| Prado, LB | 1 |
| Alessio, AM | 1 |
| Höehr, NF | 1 |
| Montalvão, S | 1 |
| Paixão, D | 1 |
| Durán, N | 1 |
| Annichino-Bizzacchi, JM | 2 |
| Li, S | 1 |
| Eisenstadt, R | 1 |
| Kumasaka, K | 1 |
| Marks, J | 1 |
| Ayata, M | 1 |
| Kaptan, Z | 1 |
| Uzunkulaoğlu, H | 1 |
| Akyıldız, İ | 1 |
| Tüzüner, A | 1 |
| Ünverdi, H | 1 |
| Karadaş, H | 1 |
| Sang, Q | 1 |
| Cui, H | 2 |
| Ozkececi, ZT | 1 |
| Gonul, Y | 1 |
| Karavelioglu, A | 1 |
| Bozkurt, MF | 1 |
| Kacar, E | 1 |
| Bal, A | 1 |
| Ozsoy, M | 1 |
| Turamanlar, O | 1 |
| Celep, B | 1 |
| Maalouly, G | 1 |
| Ward, C | 1 |
| Smayra, V | 1 |
| Saliba, Y | 1 |
| Aftimos, G | 1 |
| Haddad, F | 1 |
| Farès, N | 1 |
| Prodinger, PM | 1 |
| Burgkart, R | 1 |
| Kreutzer, K | 1 |
| Liska, F | 1 |
| Pilge, H | 1 |
| Schmitt, A | 1 |
| Knödler, M | 1 |
| Holzapfel, BM | 1 |
| Hapfelmeier, A | 1 |
| Tischer, T | 1 |
| Bissinger, O | 1 |
| Djaafar, S | 1 |
| Dunand-Sautier, I | 1 |
| Gonelle-Gispert, C | 1 |
| Lacotte, S | 1 |
| DE Agostini, A | 1 |
| Petro, M | 1 |
| Rubbia-Brandt, L | 1 |
| Morel, P | 1 |
| Toso, C | 1 |
| Mentha, G | 1 |
| King, AE | 1 |
| Jacobson, GA | 1 |
| Small, DH | 1 |
| Cavusoglu, T | 1 |
| Kismet, K | 1 |
| Ozcan, N | 1 |
| Kucuk, B | 1 |
| Barlas, AM | 1 |
| Bozkirli, BO | 1 |
| Celepli, P | 1 |
| Senes, M | 1 |
| Bolat, S | 1 |
| Hucumenoglu, S | 1 |
| Kosar, A | 1 |
| Cipil, HS | 1 |
| Kaya, A | 1 |
| Uz, B | 1 |
| Haznedaroglu, IC | 1 |
| Goker, H | 1 |
| Ozdemir, O | 1 |
| Ercetin, S | 1 |
| Kirazli, S | 1 |
| Firat, HC | 1 |
| Sood, V | 1 |
| Luke, C | 1 |
| Miller, E | 1 |
| Mitsuya, M | 1 |
| Upchurch, GR | 1 |
| Berguer, AM | 1 |
| Baker, NK | 1 |
| Lucchesi, BR | 2 |
| Timmer, NM | 1 |
| van Dijk, L | 1 |
| van der Zee, CE | 1 |
| Kiliaan, A | 1 |
| de Waal, RM | 1 |
| Verbeek, MM | 1 |
| Georgescu, A | 1 |
| Alexandru, N | 1 |
| Nemecz, M | 1 |
| Titorencu, I | 1 |
| Popov, D | 1 |
| Dos Santos Ferrari, R | 1 |
| Marcolan, AM | 1 |
| da Silva, AC | 1 |
| Graeff-Teixeira, C | 1 |
| Fornari, F | 1 |
| Sen, O | 1 |
| Sonmez, E | 1 |
| Cekinmez, M | 1 |
| Ozen, O | 1 |
| Caner, H | 1 |
| Yang, CT | 1 |
| Huang, CC | 1 |
| Kao, KC | 1 |
| Lin, HC | 1 |
| Yau, JW | 1 |
| Stafford, AR | 1 |
| Liao, P | 1 |
| Fredenburgh, JC | 1 |
| Roberts, R | 1 |
| Weitz, JI | 1 |
| Parry, TJ | 1 |
| Huang, Z | 1 |
| Chen, C | 1 |
| Connelly, MA | 1 |
| Andrade-Gordon, P | 1 |
| Damiano, BP | 1 |
| Iwatsuki, Y | 1 |
| Sato, T | 1 |
| Moritani, Y | 1 |
| Shigenaga, T | 1 |
| Suzuki, M | 1 |
| Kawasaki, T | 1 |
| Funatsu, T | 1 |
| Kaku, S | 1 |
| Schlesinger, M | 1 |
| Schmitz, P | 1 |
| Zeisig, R | 1 |
| Naggi, A | 1 |
| Torri, G | 1 |
| Casu, B | 1 |
| Bendas, G | 1 |
| Vairo, BC | 1 |
| Cinelli, LP | 1 |
| Uzan, A | 2 |
| Hong, TT | 1 |
| Driscoll, EM | 1 |
| White, AJ | 1 |
| Sherigill, A | 1 |
| Giboulot, TA | 1 |
| Ferahbas, A | 1 |
| Uksal, U | 1 |
| Kutlugun, C | 1 |
| Kontas, O | 1 |
| Quartermain, D | 3 |
| Li, YS | 2 |
| Jonas, S | 3 |
| Lavaud, S | 1 |
| Canivet, E | 1 |
| Wuillai, A | 1 |
| Maheut, H | 1 |
| Randoux, C | 1 |
| Bonnet, JM | 1 |
| Renaux, JL | 1 |
| Chanard, J | 1 |
| Bergamaschini, L | 1 |
| Rossi, E | 1 |
| Storini, C | 1 |
| Pizzimenti, S | 1 |
| Distaso, M | 1 |
| Perego, C | 1 |
| De Luigi, A | 1 |
| Vergani, C | 1 |
| De Simoni, MG | 1 |
| Röttger, C | 1 |
| Madlener, K | 1 |
| Heil, M | 1 |
| Gerriets, T | 1 |
| Walberer, M | 1 |
| Wessels, T | 1 |
| Bachmann, G | 1 |
| Kaps, M | 1 |
| Chung, TL | 1 |
| Holton, LH | 1 |
| Silverman, RP | 1 |
| De Paula, EV | 1 |
| Nascimento, MC | 1 |
| Ramos, CD | 1 |
| Ozelo, MC | 1 |
| Machado, TF | 1 |
| Guillaumon, AT | 1 |
| Arruda, VR | 1 |
| Farina, JA | 1 |
| Piccinato, CE | 1 |
| Campos, AD | 1 |
| Rossi, MA | 1 |
| Bedard, PW | 2 |
| Kaila, N | 2 |
| Shaw, G | 1 |
| Meier, TR | 3 |
| Erden, O | 1 |
| Imir, A | 1 |
| Guvenal, T | 1 |
| Muslehiddinoglu, A | 1 |
| Arici, S | 1 |
| Cetin, M | 1 |
| Cetin, A | 1 |
| Laux, V | 1 |
| Kubitza, D | 1 |
| Misselwitz, F | 1 |
| Kim, SK | 1 |
| Lee, DY | 1 |
| Kim, CY | 1 |
| Nam, JH | 1 |
| Moon, HT | 1 |
| Byun, Y | 1 |
| Zajkowski, PJ | 1 |
| Ballard, NE | 1 |
| Londy, FJ | 2 |
| Vlasuk, GP | 1 |
| Tanne, D | 1 |
| Katzav, A | 1 |
| Beilin, O | 1 |
| Grigoriadis, NC | 1 |
| Blank, M | 1 |
| Pick, CG | 1 |
| Landenberg, Pv | 1 |
| Shoenfeld, Y | 1 |
| Baxi, S | 1 |
| Crandall, DL | 1 |
| Wrobleski, S | 1 |
| Hawley, A | 1 |
| Farris, D | 1 |
| Elokdah, H | 1 |
| Sigler, R | 1 |
| Wakefield, T | 1 |
| Myers, D | 1 |
| Korompilias, AV | 1 |
| Chen, LE | 1 |
| Seaber, AV | 1 |
| Urbaniak, JR | 1 |
| Leadley, RJ | 2 |
| Kasiewski, CJ | 2 |
| Bostwick, JS | 2 |
| Bentley, R | 1 |
| Dunwiddie, CT | 1 |
| Perrone, MH | 2 |
| Chi, L | 1 |
| Saganek, LJ | 1 |
| Rogers, KL | 1 |
| Mertz, TE | 2 |
| Metz, AL | 1 |
| Uprichard, AC | 1 |
| Gallagher, KP | 1 |
| Sinha, U | 1 |
| Ku, P | 1 |
| Malinowski, J | 1 |
| Zhu, BY | 1 |
| Scarborough, RM | 1 |
| Marlowe, CK | 1 |
| Wong, PW | 1 |
| Lin, PH | 1 |
| Hollenbach, SJ | 1 |
| Gonze, MD | 1 |
| Salartash, K | 1 |
| Sternbergh, WC | 1 |
| Baughman, RA | 1 |
| Leone-Bay, A | 1 |
| Money, SR | 1 |
| Toomey, JR | 1 |
| Blackburn, MN | 1 |
| Storer, BL | 1 |
| Valocik, RE | 1 |
| Koster, PF | 1 |
| Feuerstein, GZ | 1 |
| Morris, TA | 1 |
| Marsh, JJ | 1 |
| Konopka, R | 1 |
| Pedersen, CA | 1 |
| Chiles, PG | 1 |
| Street, JT | 1 |
| McGrath, M | 1 |
| O'Regan, K | 1 |
| Wakai, A | 1 |
| McGuinness, A | 1 |
| Redmond, HP | 1 |
| Mary, V | 1 |
| Wahl, F | 1 |
| Stutzmann, JM | 1 |
| Rebello, SS | 1 |
| Bentley, RG | 1 |
| Morgan, SR | 1 |
| Chu, V | 1 |
| Klein, SI | 1 |
| Dotan, I | 1 |
| Hershkoviz, R | 1 |
| Karmeli, F | 1 |
| Brazowski, E | 1 |
| Peled, Y | 1 |
| Rachmilewitz, D | 1 |
| Halpern, Z | 1 |
| Zhu, H | 1 |
| Yu, J | 1 |
| Kindy, MS | 1 |
| McClanahan, TB | 1 |
| Hicks, GW | 1 |
| Morrison, AL | 1 |
| Peng, YW | 1 |
| Janiczek-Dolphin, N | 1 |
| Sullivan, ME | 1 |
| Morser, J | 1 |
| Juneau, PL | 1 |
| Leadley, R | 1 |
| Hiebert, LM | 3 |
| Pross, M | 1 |
| Lippert, H | 1 |
| Nestler, G | 1 |
| Kuhn, R | 1 |
| Langer, H | 1 |
| Mantke, R | 1 |
| Schulz, HU | 1 |
| Zacharski, LR | 1 |
| Fareed, J | 1 |
| Jeske, W | 1 |
| Eschenfelder, V | 1 |
| Iqbal, O | 1 |
| Hoppensteadt, D | 1 |
| Ahsan, A | 1 |
| Oberhoff, M | 1 |
| Novak, S | 1 |
| Herdeg, C | 1 |
| Baumbach, A | 1 |
| Kranzhöfer, A | 1 |
| Bohnet, A | 1 |
| Horch, B | 1 |
| Hanke, H | 1 |
| Haase, KK | 1 |
| Karsch, KR | 1 |
| Roqué, M | 1 |
| Rauch, U | 1 |
| Reis, ED | 1 |
| Chesebro, JH | 1 |
| Fuster, V | 1 |
| Badimon, JJ | 1 |
| Deepa, PR | 1 |
| Varalakshmi, P | 1 |
| Takikawa, M | 3 |
| Nakamura, S | 4 |
| Ishihara, M | 5 |
| Takabayashi, Y | 1 |
| Fujita, M | 4 |
| Hattori, H | 2 |
| Kushibiki, T | 1 |
| Shaya, SA | 1 |
| Saldanha, LJ | 1 |
| Vaezzadeh, N | 1 |
| Zhou, J | 1 |
| Ni, R | 1 |
| Gross, PL | 1 |
| Luna, RL | 1 |
| Vasconcelos, AG | 1 |
| Nunes, AK | 1 |
| de Oliveira, WH | 1 |
| Barbosa, KP | 1 |
| Peixoto, CA | 1 |
| McKellar, SH | 1 |
| Thompson, JL | 1 |
| Garcia-Rinaldi, RF | 1 |
| Macdonald, RJ | 1 |
| Sundt, TM | 1 |
| Schaff, HV | 1 |
| Pehrsson, S | 1 |
| Johansson, K | 1 |
| Kjaer, M | 1 |
| Elg, M | 1 |
| Luo, JY | 1 |
| Zhong, Y | 1 |
| Cao, JC | 1 |
| Cui, HF | 1 |
| Horio, T | 2 |
| Tanaka, Y | 1 |
| Kishimoto, S | 3 |
| Hase, K | 1 |
| Maehara, T | 2 |
| Aghourian, MN | 1 |
| Lemarié, CA | 1 |
| Blostein, MD | 1 |
| Isoda, S | 1 |
| Sato, M | 1 |
| Nakayama, T | 1 |
| Yamamoto, Y | 1 |
| Shimizu, M | 1 |
| Tachibana, S | 1 |
| Bagge, L | 1 |
| Wahlberg, T | 1 |
| Holmer, E | 1 |
| Tydén, H | 1 |
| Nyström, SO | 1 |
| Malm, T | 1 |
| Kornowski, R | 2 |
| Glikson, M | 1 |
| Hasdai, D | 2 |
| Chernine, A | 1 |
| Ohad, D | 2 |
| Battler, A | 2 |
| Tazawa, S | 1 |
| Ichikawa, K | 1 |
| Misawa, K | 1 |
| Fukuyama, J | 1 |
| Hamano, S | 1 |
| Miyata, H | 1 |
| Sakuragawa, N | 1 |
| Varda-Bloom, N | 1 |
| Blumberg, N | 1 |
| Eriksson, BI | 1 |
| Carlsson, S | 1 |
| Halvarsson, M | 1 |
| Risberg, B | 1 |
| Mattsson, C | 1 |
| Schaub, R | 1 |
| Fex, BA | 1 |
| Chapman, AM | 1 |
| Greenfield, LJ | 1 |
| Miyake, Y | 1 |
| Yokota, K | 1 |
| Fujishima, Y | 1 |
| Sukamoto, T | 1 |
| Alyahya, R | 1 |
| Sudha, T | 1 |
| Racz, M | 1 |
| Stain, SC | 1 |
| Mousa, SA | 1 |
| Bauer, AT | 1 |
| Suckau, J | 1 |
| Frank, K | 1 |
| Desch, A | 1 |
| Goertz, L | 1 |
| Wagner, AH | 1 |
| Hecker, M | 1 |
| Goerge, T | 1 |
| Umansky, L | 1 |
| Beckhove, P | 1 |
| Utikal, J | 1 |
| Gorzelanny, C | 1 |
| Diaz-Valdes, N | 1 |
| Umansky, V | 1 |
| Schneider, SW | 1 |
| Ping, T | 1 |
| Wice, SM | 2 |
| Pinel, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Influence of Ovarian Torsion and Surgical De-torsion on Ovarian Reserve[NCT03852615] | 100 participants (Anticipated) | Interventional | 2019-03-01 | Recruiting | |||
| Pilot Study of Treatment With Intravenous Enoxaparin and/or Oral Minocycline to Limit Infarct Size After Ischemic Stroke[NCT00836355] | 6 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Too few acute stroke patients available to meet enrollment requirements.) | |||
| Pilot, Prospective, Multicenter, Open and Non-randomised Study: Definition of an Index of Anti Xa Value at the End of Hemodialysis Treatment.[NCT00781690] | 53 participants (Actual) | Interventional | 2008-09-30 | Completed | |||
| Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine[NCT04507178] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-02-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for dalteparin and Disease Models, Animal
| Article | Year |
|---|---|
[Thrombosis and ischemia: experimental data].
Topics: Animals; Apoptosis; Coronary Thrombosis; Disease Models, Animal; Dogs; Enoxaparin; Fibrinolytic Agen | 2002 |
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Bleeding Time; Clinical Trials, Phase II as Topic; Di | 2007 |
Low molecular weight heparin and the treatment of ischemic stroke. Animal results, the reasons for failure in human stroke trials, mechanisms of action, and the possibilities for future use in stroke.
Topics: Animals; Anticoagulants; Calcium; Calcium Channel Blockers; Cerebral Infarction; Clinical Trials as | 2001 |
116 other studies available for dalteparin and Disease Models, Animal
| Article | Year |
|---|---|
Low molecular weight heparin (nadroparin) improves placental permeability in rats with gestational diabetes mellitus via reduction of tight junction factors.
Topics: Animals; Diabetes, Gestational; Disease Models, Animal; Female; Glycation End Products, Advanced; Na | 2020 |
Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
Topics: Administration, Oral; Animals; Anticoagulants; Arginine; Blood Coagulation Tests; Disease Models, An | 2005 |
Evaluation of two experimental venous thrombosis models in the rat.
Topics: Animals; Blood Coagulation Tests; Chlorides; Disease Models, Animal; Female; Ferric Compounds; Hemos | 2005 |
Pharmacological correction of changes in the lung-placenta system under experimental conditions.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fibrinogen; Hydrocortison | 2005 |
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation Tests; Disease Models, Animal; Dose | 2007 |
[Antithrombotic properties of heparin independent of its anticoagulant activity].
Topics: Animals; Blood Coagulation; Disease Models, Animal; Dose-Response Relationship, Drug; Heparin; Laser | 1994 |
Efficacy of prevention of thromboembolic complications with LMW-heparin in experiment.
Topics: Animals; Anticoagulants; Arthroplasty, Replacement, Hip; Disease Models, Animal; Dogs; Factor Xa Inh | 1997 |
[The effect of a DC electrical field on pancreatic function in acute pancreatitis].
Topics: Acute Disease; Animals; Anticoagulants; Aprotinin; Disease Models, Animal; Drug Evaluation, Preclini | 1998 |
Comparative study on the in vitro and in vivo activities of heparinoids derivative investigated on the animal model.
Topics: Animals; Blood Coagulation Factors; Disease Models, Animal; Fibrinolytic Agents; Heparin; Heparinoid | 1999 |
Role of parnaparin in atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cell Proliferation; Disease Models, Animal; Heparin, Lo | 2016 |
Protective role of parnaparin in reducing systemic inflammation and atherosclerotic plaque formation in ApoE-/- mice.
Topics: Animals; Apolipoproteins E; Arteries; Disease Models, Animal; Fatty Liver; Fibrinolytic Agents; Gene | 2011 |
Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat.
Topics: Administration, Rectal; Animals; Colitis; Dinitrobenzenes; Disease Models, Animal; Dose-Response Rel | 2008 |
[Anticoagulant effect of a single bolus injection of parnaparin sodium (LHG) on a hemodialysis model in dogs].
Topics: Animals; Anticoagulants; Blood Coagulation Tests; Disease Models, Animal; Dogs; Dose-Response Relati | 1994 |
LPS-Induced Coagulation and Neuronal Damage in a Mice Model Is Attenuated by Enoxaparin.
Topics: Animals; Disease Models, Animal; Enoxaparin; Inflammation; Lipopolysaccharides; Mice; Mice, Inbred C | 2022 |
Investigation of the protective effect of enoxaparin and ticagrelor pretreatment against ischemia-reperfusion injury in rat lung tissue.
Topics: Animals; Aorta, Abdominal; Apoptosis; Caspase 3; Disease Models, Animal; Enoxaparin; Lung; Lung Inju | 2019 |
Low-Molecular-Weight Heparin Reduces Ventilation-Induced Lung Injury through Hypoxia Inducible Factor-1α in a Murine Endotoxemia Model.
Topics: Animals; Anti-Inflammatory Agents; Chemokine CXCL2; Disease Models, Animal; Endotoxemia; Enoxaparin; | 2020 |
Enoxaparin Attenuates Acute Lung Injury and Inflammasome Activation after Traumatic Brain Injury.
Topics: Acute Lung Injury; Animals; Anticoagulants; Brain Injuries, Traumatic; Disease Models, Animal; Enoxa | 2021 |
Antithrombin III ameliorates post-traumatic brain injury cerebral leukocyte mobilization enhancing recovery of blood brain barrier integrity.
Topics: Animals; Antithrombin III; Blood-Brain Barrier; Brain Hemorrhage, Traumatic; Cell Migration Assays, | 2021 |
Oral administration of dermatan sulphate reduces venous thrombus formation in vivo: potential use as a formulation for venous thromboembolism.
Topics: Administration, Oral; Animals; Anticoagulants; Cattle; Collagen; Dermatan Sulfate; Disease Models, A | 2021 |
High-dose enoxaparin in the treatment of abdominal angiostrongyliasis in Swiss mice.
Topics: Animals; Anticoagulants; Disease Models, Animal; Enoxaparin; Infarction; Mesenteric Arteries; Mice; | 2018 |
Effects of aspirin and enoxaparin in a rat model of liver fibrosis.
Topics: Animals; Antithrombins; Aspirin; Disease Models, Animal; Enoxaparin; Liver; Liver Cirrhosis, Experim | 2017 |
Combined Treatment with an Anticoagulant and a Vasodilator Prevents Steroid-Associated Osteonecrosis of Rabbit Femoral Heads by Improving Hypercoagulability.
Topics: Animals; Anticoagulants; Bone Morphogenetic Protein 2; Disease Models, Animal; Enoxaparin; Femur Hea | 2017 |
Enoxaparin pretreatment effect on local and systemic inflammation biomarkers in the animal burn model.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Antithrombin III; Biomarkers; Burns; C-Reactive P | 2019 |
Systemic administration of heparin ameliorates radiation-induced oral mucositis-preclinical studies in mice.
Topics: Animals; Disease Models, Animal; Enoxaparin; Heparin; Humans; Injections, Subcutaneous; Mice; Mice, | 2018 |
A concomitant bone fracture delays cognitive recovery from traumatic brain injury.
Topics: Animals; Behavior, Animal; Brain; Brain Injuries, Traumatic; Cognition; Disease Models, Animal; Enox | 2018 |
The impact of enoxaparin administration in relationship to hemorrhage in mild traumatic brain injury.
Topics: Animals; Anticoagulants; Brain Concussion; Disease Models, Animal; Enoxaparin; Intracranial Hemorrha | 2018 |
The Role of Chemoprophylactic Agents in Modulating Platelet Aggregability After Traumatic Brain Injury.
Topics: Amitriptyline; Animals; Aspirin; Blood Coagulation; Brain Injuries, Traumatic; Disease Models, Anima | 2019 |
Evaluation of the effects of hyperbaric oxygen treatment and enoxaparin on left colon anastomosis. An experimental study.
Topics: Anastomosis, Surgical; Animals; Anticoagulants; Collagen; Colon; Combined Modality Therapy; Disease | 2013 |
Histopathological effects of different therapy strategies in experimental sinus thrombosis.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Astrocytes; Brain; Chlorides; Collateral Circulation; Di | 2014 |
Effects of enoxaparin and rivaroxaban on tissue survival in skin degloving injury: an experimental study.
Topics: Animals; Disease Models, Animal; Enoxaparin; Fibrinolytic Agents; Inflammation; Male; Morpholines; N | 2014 |
In vitro and in vivo evaluation of chitosan graft glyceryl monooleate as peroral delivery carrier of enoxaparin.
Topics: Adhesiveness; Administration, Oral; Animals; Anticoagulants; Caco-2 Cells; Chitosan; Disease Models, | 2014 |
Effect of detorsion alone and in combination with enoxaparin therapy on ovarian reserve and serum antimüllerian hormone levels in a rat ovarian torsion model.
Topics: Animals; Anti-Mullerian Hormone; Cell Count; Combined Modality Therapy; Disease Models, Animal; Enox | 2014 |
Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombin III; Disease Models, Animal; Drug Admini | 2014 |
Structural and functional analyses of biosimilar enoxaparins available in Brazil.
Topics: Animals; Anticoagulants; Biosimilar Pharmaceuticals; Blood Coagulation; Blood Coagulation Tests; Bra | 2015 |
P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor.
Topics: Animals; Aptamers, Nucleotide; Blood Coagulation; Collagen; Disease Models, Animal; Enoxaparin; Fibr | 2015 |
Orally Administered Enoxaparin Ameliorates Acute Colitis by Reducing Macrophage-Associated Inflammatory Responses.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Anticoagulants; Colitis; Cytokines; Dextran Sulfat | 2015 |
Polymeric Nanoparticles of Enoxaparin as a Delivery System: In Vivo Evaluation in Normal Rats and in a Venous Thrombosis Rat Model.
Topics: Animals; Anticoagulants; Disease Models, Animal; Drug Delivery Systems; Enoxaparin; Male; Nanopartic | 2015 |
Does enoxaparin interfere with HMGB1 signaling after TBI? A potential mechanism for reduced cerebral edema and neurologic recovery.
Topics: Animals; Antibodies, Monoclonal; Anticoagulants; Brain; Brain Edema; Brain Injuries; Cerebrovascular | 2016 |
Effect of Enoxaparin Sodium on Experimentally-Induced Myringosclerosis in Rats.
Topics: Animals; Anticoagulants; Calcinosis; Disease Models, Animal; Enoxaparin; Fibrosis; Hyalin; Hyperemia | 2015 |
Preparation and evaluation a new generation of low molecular weight heparin.
Topics: Animals; Anticoagulants; Antithrombins; Disease Models, Animal; Enoxaparin; Factor Xa Inhibitors; He | 2016 |
The effect of enoxaparin on seroma and mesh-tissue adhesion in a hernia model.
Topics: Animals; Disease Models, Animal; Enoxaparin; Hernia; Inflammation; Male; Polypropylenes; Rats; Rats, | 2016 |
Fish oil attenuates neurologic severity of antiphospholipid syndrome in a mice experimental model.
Topics: Animals; Antiphospholipid Syndrome; Anxiety; Behavior, Animal; Brain; Curcumin; Disease Models, Anim | 2017 |
Does Anticoagulant Medication Alter Fracture-Healing? A Morphological and Biomechanical Evaluation of the Possible Effects of Rivaroxaban and Enoxaparin Using a Rat Closed Fracture Model.
Topics: Animals; Anticoagulants; Biomechanical Phenomena; Disease Models, Animal; Enoxaparin; Fracture Heali | 2016 |
Enoxaparin Attenuates Mouse Colon Cancer Liver Metastases by Inhibiting Heparanase and Interferon-γ-inducible Chemokines.
Topics: Animals; Chemokines; Colonic Neoplasms; Disease Models, Animal; Enoxaparin; Gene Expression Regulati | 2016 |
Peripheral treatment with enoxaparin exacerbates amyloid plaque pathology in Tg2576 mice.
Topics: ADAM10 Protein; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Pr | 2017 |
The effects of enoxaparin on the liver in experimental pneumoperitoneum model.
Topics: Animals; Anticoagulants; Carbon Dioxide; Disease Models, Animal; Enoxaparin; Female; Liver; Oxidativ | 2016 |
The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model.
Topics: Analysis of Variance; Animals; Anticoagulants; Aspirin; Disease Models, Animal; Enoxaparin; Female; | 2009 |
Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline.
Topics: Animals; Disease Models, Animal; Doxycycline; Elasticity; Enoxaparin; Fibrin Fibrinogen Degradation | 2010 |
Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model.
Topics: Animals; Blood Coagulation; Disease Models, Animal; Electrolysis; Endothelial Cells; Enoxaparin; Fib | 2010 |
Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition Disorders; Disease Models, Animal; Enox | 2010 |
Enoxaparin reduces adrenergic contraction of resistance arterioles in aging and in aging associated with diabetes via engagement of MAP kinase pathway.
Topics: Adrenergic Agents; Aging; Animals; Arterioles; Cricetinae; Diabetes Mellitus, Experimental; Diabetes | 2011 |
Outcomes in mice with abdominal angiostrongyliasis treated with enoxaparin.
Topics: Angiostrongylus; Animals; Anthelmintics; Chemoprevention; Disease Models, Animal; Enoxaparin; Histoc | 2011 |
Antithrombin III and enoxaparin treatment inhibit contusion-triggered cell death, inflammation, hemorrhage and apoptosis after severe traumatic brain injury in rats.
Topics: Animals; Anticoagulants; Antithrombin III; Antithrombins; Apoptosis; Brain Injuries; Disease Models, | 2011 |
Low-molecular-weight heparin reduces hyperoxia-augmented ventilator-induced lung injury via serine/threonine kinase-protein kinase B.
Topics: Animals; Blotting, Western; Capillary Permeability; Disease Models, Animal; Enoxaparin; HMGB1 Protei | 2011 |
Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo.
Topics: Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Catheters; Dis | 2011 |
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Carotid Artery Injuries; Coronary | 2011 |
Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Azepines; Benzamides; Bleeding Time; Disease Models, | 2011 |
The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Topics: Acetylation; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Cell Adhesion; Cell Line, T | 2012 |
Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
Topics: Animals; Anticoagulants; Blood Coagulation; Brazil; Disease Models, Animal; Drugs, Generic; Enoxapar | 2012 |
Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, preven
Topics: Animals; Aspirin; Blood Coagulation; Coronary Thrombosis; Dipeptides; Disease Models, Animal; Dogs; | 2003 |
Low-molecular-weight heparin (enoxaparin) in the treatment of lichen planus.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Ad | 2003 |
The low molecular weight heparin enoxaparin reduces infarct size in a rat model of temporary focal ischemia.
Topics: Animals; Anticoagulants; Brain Infarction; Brain Ischemia; Disease Models, Animal; Drug Administrati | 2003 |
Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
Topics: Acrylic Resins; Animals; Anticoagulants; Biocompatible Materials; Disease Models, Animal; Dose-Respo | 2003 |
Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Cerebral Cortex; Complement Activatio | 2004 |
Is heparin treatment the optimal management for cerebral venous thrombosis? Effect of abciximab, recombinant tissue plasminogen activator, and enoxaparin in experimentally induced superior sagittal sinus thrombosis.
Topics: Abciximab; Angiography; Animals; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Chlorides; | 2005 |
The effect of fondaparinux versus enoxaparin in the survival of a congested skin flap in a rabbit model.
Topics: Animals; Anticoagulants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administrati | 2006 |
Early in vivo anticoagulation inhibits the angiogenic response following hindlimb ischemia in a rodent model.
Topics: Animals; Anticoagulants; Blood Coagulation Factors; Disease Models, Animal; Enoxaparin; Hindlimb; Hi | 2006 |
Comparative study of isovolemic hemodilution with 3% albumin, dextran-40, and prophylactic enoxaparin (LMWH) on thrombus formation at venous microanastomosis in rats.
Topics: Anastomosis, Surgical; Animals; Dextrans; Disease Models, Animal; Drug Therapy, Combination; Enoxapa | 2006 |
Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis.
Topics: Animals; Anticoagulants; Constriction, Pathologic; Disease Models, Animal; Enoxaparin; Fibrosis; Hyd | 2006 |
Investigation of the effects of heparin and low molecular weight heparin on E-cadherin and laminin expression in rat pregnancy by immunohistochemistry.
Topics: Abortion, Spontaneous; Animals; Anticoagulants; Cadherins; Disease Models, Animal; Enoxaparin; Femal | 2006 |
Acute enoxaparin treatment widens the therapeutic window for tPA in a mouse model of embolic stroke.
Topics: Animals; Behavior, Animal; Brain Infarction; Disease Models, Animal; Drug Interactions; Enoxaparin; | 2007 |
A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
Topics: Administration, Oral; Animals; Anticoagulants; Capsules; Chemistry, Pharmaceutical; Deoxycholic Acid | 2007 |
Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Blood Platelets; Disease Models, A | 2008 |
Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome.
Topics: Alprostadil; Analysis of Variance; Animals; Antiphospholipid Syndrome; Aspirin; Behavior, Animal; be | 2008 |
Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxaparin; Fibrosis; Indoleaceti | 2008 |
Antithrombotic potencies of enoxaparin in microvascular surgery: influence of dose and administration methods on patency rate of crushed arterial anastomoses.
Topics: Administration, Topical; Anastomosis, Surgical; Animals; Anticoagulants; Disease Models, Animal; Dos | 1997 |
Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.
Topics: Animals; Anticoagulants; Coronary Thrombosis; Coronary Vessels; Disease Models, Animal; Dogs; Dose-R | 1998 |
A novel model of venous thrombosis in the vena cava of rabbits.
Topics: Animals; Bleeding Time; Blood Coagulation; Disease Models, Animal; Enoxaparin; Fibrinolytic Agents; | 1998 |
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Antithrombins; Arteriovenous Shunt, Surgic | 2000 |
Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis.
Topics: Administration, Oral; Animals; Anticoagulants; Caprylates; Disease Models, Animal; Drug Carriers; En | 2000 |
Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis.
Topics: Animals; Antibodies, Monoclonal; Blood Coagulation Tests; Blood Flow Velocity; Carotid Artery Thromb | 2000 |
Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism.
Topics: Animals; Antibodies; Anticoagulants; Balloon Occlusion; Dalteparin; Diagnostic Imaging; Disease Mode | 2000 |
Thromboprophylaxis using a low molecular weight heparin delays fracture repair.
Topics: Animals; Anticoagulants; Biomechanical Phenomena; Bone and Bones; Bony Callus; Disease Models, Anima | 2000 |
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity.
Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa | 2001 |
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity.
Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa | 2001 |
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity.
Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa | 2001 |
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity.
Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa | 2001 |
Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs.
Topics: Animals; Blood Flow Velocity; Coronary Thrombosis; Disease Models, Animal; Dogs; Drug Therapy, Combi | 2001 |
Heparin and low-molecular-weight heparin (enoxaparin) significantly ameliorate experimental colitis in rats.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Benzenesulfonates; Colitis; Disease Models, Anima | 2001 |
Inhibition of amyloidosis using low-molecular-weight heparins.
Topics: Amyloid; Amyloidosis; Animals; Circular Dichroism; Dalteparin; Disease Models, Animal; Enoxaparin; F | 2001 |
The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
Topics: Amidines; Animals; Anticoagulants; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; E | 2001 |
Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Disease M | 2017 |
Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study.
Topics: Abdominal Neoplasms; Adenocarcinoma; Animals; Anticoagulants; Disease Models, Animal; Dose-Response | 2004 |
Heparin treatment of malignancy: the case for clinical trials in colon cancer.
Topics: Adenocarcinoma; Animals; Anticoagulants; Clinical Trials as Topic; Colonic Neoplasms; Disease Models | 2003 |
Preclinical studies on a low molecular weight heparin.
Topics: Animals; Anticoagulants; Blood Coagulation; Disease Models, Animal; Dose-Response Relationship, Drug | 1996 |
Local and systemic delivery of low molecular weight heparin stimulates the reendothelialization after balloon angioplasty.
Topics: Administration, Cutaneous; Administration, Topical; Angioplasty, Balloon; Animals; Arteriosclerosis; | 1998 |
Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivo model of deep arterial injury.
Topics: Adenosine Diphosphate; Animals; Arteries; Blood Coagulation Tests; Blood Flow Velocity; Collagen; Di | 2000 |
Favourable modulation of the inflammatory changes in hypercholesterolemic atherogenesis by a low-molecular-weight heparin derivative.
Topics: Animals; Anticoagulants; Atherosclerosis; Biomarkers; Blood Proteins; Disease Models, Animal; Hepari | 2006 |
Improved angiogenesis and healing in crush syndrome by fibroblast growth factor-2-containing low-molecular-weight heparin (Fragmin)/protamine nanoparticles.
Topics: Animals; Anticoagulants; Crush Syndrome; Dalteparin; Disease Models, Animal; Drug Evaluation, Precli | 2015 |
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Topics: Animals; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Disease Models, Animal; Disease Prog | 2016 |
Effects of Sildenafil Citrate and Heparin Treatments on Placental Cell Morphology in a Murine Model of Pregnancy Loss.
Topics: Abortion, Habitual; Animals; Anticoagulants; Dalteparin; Disease Models, Animal; Female; Lipopolysac | 2016 |
Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine.
Topics: Administration, Oral; Animals; Aspirin; Bioprosthesis; Clopidogrel; Dalteparin; Disease Models, Anim | 2008 |
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Topics: Amidines; Animals; Antithrombin III; Antithrombins; Azetidines; Blood Coagulation; Chlorides; Daltep | 2010 |
Efficacy of oral colon-specific delivery capsule of low-molecular-weight heparin on ulcerative colitis.
Topics: Administration, Oral; Animals; Anticoagulants; Colitis, Ulcerative; Colon; Dalteparin; Disease Model | 2011 |
Efficacy of fragmin/protamine microparticles containing fibroblast growth factor-2 (F/P MPs/FGF-2) to induce collateral vessels in a rabbit model of hindlimb ischemia.
Topics: Actins; Analysis of Variance; Angiogenesis Inducing Agents; Animals; Anticoagulants; Blood Pressure; | 2011 |
In vivo monitoring of venous thrombosis in mice.
Topics: Animals; Anticoagulants; Blood Coagulation; Chlorides; Dalteparin; Disease Models, Animal; Ferric Co | 2012 |
Attenuation of limb loss in an experimentally induced hindlimb ischemic model by fibroblast growth factor-2/fragmin/protamine microparticles as a delivery system.
Topics: Animals; Capillaries; Dalteparin; Disease Models, Animal; Drug Delivery Systems; Fibroblast Growth F | 2012 |
Effects of platelet-rich plasma-containing fragmin/protamine microparticles in enhancing endothelial and smooth muscle cell growth and inducing collateral vessels in a rabbit model of hindlimb ischemia.
Topics: Animals; Cells, Cultured; Dalteparin; Disease Models, Animal; Hindlimb; Ischemia; Male; Microspheres | 2013 |
Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model.
Topics: Animals; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Dalteparin; Dise | 1994 |
Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits.
Topics: Animals; Dalteparin; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination | 1994 |
Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits.
Topics: Animals; Anticoagulants; Antithrombin III; Dalteparin; Disease Models, Animal; Disseminated Intravas | 1995 |
The effect of low molecular weight heparin (fragmin) on myocardial neutrophil accumulation and infarct size in a rat model of myocardial infarction.
Topics: Animals; Anticoagulants; Dalteparin; Disease Models, Animal; Heart; Lymphocyte Activation; Male; Myo | 1996 |
Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Topics: Animals; Azetidines; Benzylamines; Dalteparin; Disease Models, Animal; Fibrinolytic Agents; Glycine; | 1997 |
P-selectin antagonism causes dose-dependent venous thrombosis inhibition.
Topics: Animals; Anticoagulants; Balloon Occlusion; Dalteparin; Disease Models, Animal; Dose-Response Relati | 2001 |
The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat.
Topics: Animals; Anticoagulants; Antithrombin III; Bleeding Time; Chondroitin Sulfates; Dalteparin; Dermatan | 2001 |
Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models.
Topics: Animals; Anticoagulants; Disease Models, Animal; Female; Heparin; Heparin, Low-Molecular-Weight; Hum | 2015 |
von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.
Topics: ADAM Proteins; ADAMTS13 Protein; Animals; Blood Coagulation; Blood Platelets; Disease Models, Animal | 2015 |
Repeated doses of oral and subcutaneous heparins have similar antithrombotic effects in a rat carotid arterial model of thrombosis.
Topics: Administration, Oral; Animals; Carotid Artery Thrombosis; Disease Models, Animal; Fibrinolytic Agent | 2012 |
Orally administered heparins prevent arterial thrombosis in a rat model.
Topics: Administration, Oral; Animals; Blood Flow Velocity; Carotid Artery Thrombosis; Disease Models, Anima | 2004 |